Why the "Y" Becomes a "Trans-Y": Validation of the "Number Y" for Implant Height Prediction in Gender-Affirming Breast Augmentation Using Anatomical Implants

为什么“Y”变成了“跨性别Y”:使用解剖型假体进行性别肯定隆胸手术时,“数字Y”对假体高度预测的验证

阅读:2

Abstract

Breast augmentation is the most frequently performed gender-affirming surgery (GAS) for transfeminine individuals. Because of anatomical differences between transfeminine and cisgender women, implant selection requires tailored planning. The "Number Y" is an established method for implant height selection in cisgender patients. Since its adoption for transfeminine patients at our institution in 2016, its reliability in this population has not been validated. The aim of this study was to validate the Number Y in transfeminine patients, identify anatomical factors influencing implant height prediction, and propose an adjusted "Number trans-Y" to improve surgical planning. This retrospective study included 21 transfeminine patients undergoing breast augmentation as part of GAS. Preoperative implant height predictions using the Number Y were compared with actual intraoperative implant choices. Implant shapes were categorized as vertical-elliptical, circular, or horizontal-elliptical. Patient and implant characteristics were analyzed for concordance. The mean patient age was 39.62 years, BMI of 25.42, and the mean Number Y of 4.31, higher than reported in cisgender cohorts. Implant height prediction was accurate in 16 patients (76.19%). Discordant cases (23.81%) had significantly smaller thoracic perimeters (9 cm difference, P = .01) and lower Number Y (3.96 ± 0.11 vs 4.42 ± 0.28; P < .001). Most concordant cases received low-height implants, whereas discordant cases were predicted to require middle-height implants but ultimately received low-height implants. The Number Y has limited predictive accuracy in transfeminine patients because of distinct thoracic anatomy and higher Y factors. An adjusted Number trans-Y is proposed to optimize implant selection and surgical outcomes in this population. Level of Evidence: 4 (Therapeutic).

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。